Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GSK licenses Vertex pain-relief drug
Vertex will receive a $20 million up-front payment and could receive up to an additional $385 million in development and sales threshold milestone payments based on the development
Vertex will receive a $20 million up-front payment and could receive up to an additional $385 million in development and sales threshold milestone payments based on the development
The primary objective of the phase I study will be to evaluate the safety and tolerability of single escalating doses of SIGA-246, and will be performed at the
The filing represents the ninth milestone that the companies have achieved in the collaboration and triggers a milestone payment to Roche. In the collaboration, Genmab utilizes its antibody
Arformoterol is the first long-acting bronchodilator to be developed in an inhalation solution for use with a nebulizer. Other long-acting bronchodilators currently available are formulated in dry-powder inhalers
Postmenopausal women in the trial who switched from placebo to Femara experienced a 69% reduction in the risk that their breast cancer would return. There also was a
Iplex is specifically approved to treat children with severe primary IGF-1 deficiency or with growth hormone gene deletion who have developed neutralizing antibodies to growth hormones. The drug
The company is to make the filing after a pivotal trial showed two years of maintenance therapy with the drug, known as Rituxan in the US, dramatically improved
The interim analysis was performed following AstraZeneca’s decision to expand the size of the “Saint II” trial from 1,700 to 3,200 patients and included safety data from 1,597
In the trial the drug, an oral endothelin receptor antagonist, met the primary efficacy endpoint of improved exercise capacity, the key secondary endpoint of time to clinical worsening
Immune thrombocytopenic purpura (ITP) is characterized by an immune system malfunction that recognizes the body’s own platelets as foreign and destroys them, potentially resulting in dangerously low platelet